Compare Fresenius Kabi Onco. with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SHASUN PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SHASUN PHARMA FRESENIUS KABI ONCO./
SHASUN PHARMA
 
P/E (TTM) x 22.1 123.9 17.9% View Chart
P/BV x 3.1 8.5 36.5% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 FRESENIUS KABI ONCO.   SHASUN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SHASUN PHARMA
Mar-14
FRESENIUS KABI ONCO./
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs17694 186.8%   
Low Rs7946 172.1%   
Sales per share (Unadj.) Rs37.7214.2 17.6%  
Earnings per share (Unadj.) Rs5.15.3 95.5%  
Cash flow per share (Unadj.) Rs6.715.8 42.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs42.553.3 79.8%  
Shares outstanding (eoy) m158.2356.62 279.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,034.6%   
Avg P/E ratio x25.013.1 190.7%  
P/CF ratio (eoy) x18.94.4 428.4%  
Price / Book Value ratio x3.01.3 228.2%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m20,1353,958 508.7%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7032,164 32.5%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96312,127 49.2%  
Other income Rs m18229 7.8%   
Total revenues Rs m5,98112,356 48.4%   
Gross profit Rs m1,4301,009 141.7%  
Depreciation Rs m258594 43.4%   
Interest Rs m-26415 -6.3%   
Profit before tax Rs m1,216230 529.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-73 -470.6%   
Profit after tax Rs m806302 266.7%  
Gross profit margin %24.08.3 288.2%  
Effective tax rate %28.1-31.7 -88.9%   
Net profit margin %13.52.5 542.5%  
BALANCE SHEET DATA
Current assets Rs m5,1026,884 74.1%   
Current liabilities Rs m2,3858,456 28.2%   
Net working cap to sales %45.6-13.0 -351.5%  
Current ratio x2.10.8 262.7%  
Inventory Days Days15062 243.4%  
Debtors Days Days113108 105.3%  
Net fixed assets Rs m5,1484,970 103.6%   
Share capital Rs m158113 139.6%   
"Free" reserves Rs m6,5562,875 228.0%   
Net worth Rs m6,7323,020 222.9%   
Long term debt Rs m9521,817 52.4%   
Total assets Rs m10,38813,347 77.8%  
Interest coverage x-45.81.6 -2,947.0%   
Debt to equity ratio x0.10.6 23.5%  
Sales to assets ratio x0.60.9 63.2%   
Return on assets %7.55.4 139.7%  
Return on equity %12.010.0 119.7%  
Return on capital %14.613.3 109.6%  
Exports to sales %74.546.4 160.6%   
Imports to sales %24.814.2 173.9%   
Exports (fob) Rs m4,4415,622 79.0%   
Imports (cif) Rs m1,4771,728 85.5%   
Fx inflow Rs m5,2985,843 90.7%   
Fx outflow Rs m1,7722,173 81.6%   
Net fx Rs m3,5253,669 96.1%   
CASH FLOW
From Operations Rs m1,274398 320.4%  
From Investments Rs m-1,204-1,635 73.7%  
From Financial Activity Rs m-1961,309 -15.0%  
Net Cashflow Rs m-12671 -177.4%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.6 8.3%  
FIIs % 9.6 17.6 54.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 39.6 23.0%  
Shareholders   42,599 20,750 205.3%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ELDER PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS